View All Pages

Leukemia - B-cell Prolymphocytic Leukemia and Hairy Cell Leukemia - Overview

This section has been reviewed and approved by the Cancer.Net Editorial Board, 06/2014

ON THIS PAGE: You will find some basic information about this disease and the parts of the body it may affect. This is the first page of Cancer.Net’s Guide to B-Cell Leukemia. To see other pages, use the menu on the side of your screen. Think of that menu as a roadmap to this full guide.

About leukemia

Leukemia is a cancer of the blood cells. Leukemia begins when normal blood cells change and grow uncontrollably. Blood cells are made in the bone marrow, the spongy tissue inside the larger bones in the body. There are different types of blood cells, including red blood cells that carry oxygen throughout the body, white cells that fight infection, and platelets that help the blood to clot. Types of leukemia are named after the specific blood cell that becomes cancerous, such as the lymphoid cells, which are white blood cells, or the myeloid cells, which are cells of the bone marrow that develop into cells that fight bacterial infections. There are four main types of leukemia in adults:

About PLL and HCL

There are other, less common types of leukemia, but they are generally subcategories of one of the four main categories. This section focuses on prolymphocytic leukemia (PLL) and hairy cell leukemia (HCL), both of which are chronic B-cell leukemias. B cells are a specific type of lymphocyte that normally make antibodies for the immune system.

In PLL, many immature lymphocytes, or prolymphocytes, are found in the blood. This type of leukemia may occur by itself, together with CLL, or CLL may turn into PLL.  PLL tends to worsen more quickly than CLL.

HCL is a slow-growing form of leukemia. It is called “hairy cell” because the abnormal lymphocytes have projections that look like hair when seen under a microscope. As these cells multiply, they build up in the bone marrow, blood, and spleen. Because these lymphocytes are abnormal, they do not work normally to fight disease and infection, and eventually may crowd out the normal cells. Treatment is usually very effective for HCL.

Looking for More of an Overview?

If you would like additional introductory information, explore these related items on Cancer.Net. Please note these links take you to other sections on Cancer.Net:

To continue reading this guide, use the menu on the side of your screen to select another section.

Leukemia - B-cell Prolymphocytic Leukemia and Hairy Cell Leukemia - Statistics

This section has been reviewed and approved by the Cancer.Net Editorial Board, 06/2014

ON THIS PAGE: You will find information about how many people learn they have leukemia each year and some general survival information. Remember, survival rates depend on several factors. To see other pages, use the menu on the side of your screen.

This year, an estimated 52,380 people of all ages (30,100 men and boys and 22,280 women and girls) in the United States will be diagnosed with leukemia. HCL accounts for about 2% of all leukemia diagnoses. An estimated 15,720 people (9,100 men and boys and 6,620 women and girls) in the United States will be diagnosed with CLL this year, though CLL is rare in children. There are no current estimates for how many people develop PLL.

Cancer statistics should be interpreted with caution. Estimates are based on data from thousands of people with this type of cancer in the United States, but the actual risk for a particular individual may differ. It is not possible to tell a person how long he or she will live with B-cell leukemia. Learn more about understanding statistics.

Statistics adapted from the American Cancer Society's publication, Cancer Facts and Figures 2014, and the ACS website.

To continue reading this guide, use the menu on the side of your screen to select another section.

Leukemia - B-cell Prolymphocytic Leukemia and Hairy Cell Leukemia - Risk Factors

This section has been reviewed and approved by the Cancer.Net Editorial Board, 06/2014

ON THIS PAGE: You will find out more about the factors that increase the chance of developing PLL or HCL. To see other pages, use the menu on the side of your screen.

A risk factor is anything that increases a person’s chance of developing cancer. Although risk factors often influence the development of cancer, most do not directly cause cancer. Some people with several risk factors never develop cancer, while others with no known risk factors do. However, knowing your risk factors and talking about them with your doctor may help you make more informed lifestyle and health care choices.

In general, leukemia can sometimes be caused by a genetic mutation or change that is passed from generation to generation within a family or environmental factors, such as smoking, or chemical or radiation exposure. However, most often the cause of leukemia is not known.

The following factors may raise a person’s risk of developing PLL or HCL:

Age. HCL occurs most often in people between ages 40 and 70.

Gender. Men are five times more likely to develop HCL than women.

Race/Ethnicity. HCL is more common in white people and Ashkenazi Jewish men. PLL and HCL are rare in people of Japanese or Southeast Asian descent.

To continue reading this guide, use the menu on the side of your screen to select another section.

Leukemia - B-cell Prolymphocytic Leukemia and Hairy Cell Leukemia - Symptoms and Signs

This section has been reviewed and approved by the Cancer.Net Editorial Board, 06/2014

ON THIS PAGE: You will find out more about body changes and other things that can signal a problem that may need medical care. To see other pages, use the menu on the side of your screen.

People with HCL or PLL may experience the following symptoms or signs. Sometimes, people with HCL or PLL do not show any of these symptoms. Or, these symptoms may be caused by a medical condition that is not cancer.

  • Enlarged lymph nodes in PLL. In HCL, hairy cells build up more often in the spleen and bone marrow and may not cause noticeable lymph node swelling.
  • Tendency to bruise easily
  • Slow wound healing
  • Weight loss
  • Unexplained fatigue
  • Persistent, unexplained abdominal pain on the left side, due to an enlarged spleen
  • Frequent infections

If you are concerned about one or more of the symptoms or signs on this list, please talk with your doctor. Your doctor will ask how long and how often you’ve been experiencing the symptom(s), in addition to other questions. This is to help find out the cause of the problem, called a diagnosis.

If HCL or PLL is diagnosed, relieving symptoms remains an important part of care and treatment. This may also be called symptom management, palliative care, or supportive care. Be sure to talk with your health care team about symptoms you experience, including any new symptoms or a change in symptoms.

The next section helps explain what tests and scans may be needed to learn more about the cause of the symptoms. Use the menu on the side of your screen to select Diagnosis, or you can select another section, to continue reading this guide.

Leukemia - B-cell Prolymphocytic Leukemia and Hairy Cell Leukemia - Diagnosis

This section has been reviewed and approved by the Cancer.Net Editorial Board, 06/2014

ON THIS PAGE: You will find a list of the common tests, procedures, and scans that doctors can use to find out what’s wrong and identify the cause of the problem. To see other pages, use the menu on the side of your screen.

Doctors use many blood and bone marrow tests to diagnose both HCL and PLL and to find out how much the disease has spread. Although a patient’s signs and symptoms may cause a doctor to suspect HCL or PLL, it is diagnosed only by blood and bone marrow tests. Some tests may also determine which treatments may be the most effective. This list describes options for diagnosing HCL and PLL, and not all tests listed will be used for every person. Your doctor may consider these factors when choosing a diagnostic test:

  • Age and medical condition
  • Type of cancer suspected
  • Signs and symptoms
  • Previous test results

The following tests may be used to diagnose PLL and HCL:

Blood tests. The diagnosis of PLL or HCL begins with a blood test, called a complete blood count (CBC). A CBC measures the numbers of different types of cells in a person's blood. If the blood contains many white blood cells, a type of B-cell leukemia may be suspected. However, patients with HCL often have very low levels of white blood cells.

Bone marrow aspiration and biopsy. These two procedures are similar and often done at the same time to examine the bone marrow. Bone marrow has both a solid and a liquid part. A bone marrow aspiration removes a sample of fluid with a needle. A bone marrow biopsy is the removal of a small amount of solid tissue using a needle. The sample(s) are then analyzed by a pathologist to determine the number and type of abnormal cells. A pathologist is a doctor who specializes in interpreting laboratory tests and evaluating cells, tissues, and organs to diagnose disease. A common site for the bone marrow aspiration and biopsy is the pelvic bone, which is located in the lower back by the hip. The skin in that area is usually numbed with medication beforehand, and other types of anesthesia (medication to block the awareness of pain) may be used.

Molecular testing. Your doctor may recommend running laboratory tests on a bone marrow sample to identify specific genes, proteins, and other factors unique to the leukemia. Immunophenotyping is the examination of antigens, a specific type of protein, on the surface of the leukemia cells. Immunophenotyping allows the doctor to confirm the exact type of leukemia. Cytogenetics is the examination of the leukemia cells for abnormalities in the long strands of genes called chromosomes. It helps the doctor confirm the diagnosis and may help to determine the person’s chance of recovery. Results of these tests will also help decide whether your treatment options include a type of treatment called targeted therapy (see Treatment Options).

Computed tomography (CT or CAT) scan. A CT scan creates a three-dimensional picture of the inside of the body with an x-ray machine. A computer then combines these images into a detailed, cross-sectional view that shows any abnormalities or tumors. A CT scan also shows enlarged lymph nodes or a swollen spleen and can be used to measure the size of a swollen lymph node. Sometimes, a special dye called a contrast medium is given before the scan to provide better detail on the image. This dye can be injected into a patient’s vein or given as a pill to swallow.

After diagnostic tests are done, your doctor will review all of the results with you. If the diagnosis is HCL or PLL, these results also help the doctor describe the leukemia.

To continue reading this guide, use the menu on the side of your screen to select another section.

Leukemia - B-cell Prolymphocytic Leukemia and Hairy Cell Leukemia - Stages

This section has been reviewed and approved by the Cancer.Net Editorial Board, 06/2014

ON THIS PAGE: You will learn about how doctors describe the growth or spread of most types of cancer, called stage, and how this differs for HCL and PLL. To see other pages, use the menu on the side of your screen.

Generally, staging is a way of describing where the cancer is located, if or where it has spread, and whether it is affecting other parts of the body. Unlike most solid tumors, HCL and PLL do not have a formal staging system. However, doctors still use diagnostic tests, such as those discussed in the Diagnosis section to evaluate HCL and PLL to help decide what kind of treatment is best and predict your prognosis, which is the chance of recovery. Talk with your doctor for details on how your specific type of leukemia will be evaluated.

The next section helps explain the treatment options for these types of leukemia. Use the menu on the side of your screen to select Treatment Options, or you can select another section, to continue reading this guide.

Leukemia - B-cell Prolymphocytic Leukemia and Hairy Cell Leukemia - Treatment Options

This section has been reviewed and approved by the Cancer.Net Editorial Board, 06/2014

ON THIS PAGE: You will learn about the different ways doctors use to treat people with HCL and PLL. To see other pages, use the menu on the side of your screen.

This section outlines treatments that are the standard of care (the best proven treatments available) for HCL and PLL. When making treatment plan decisions, patients are also encouraged to consider clinical trials as an option. A clinical trial is a research study to test a new approach to treatment to evaluate whether it is safe, effective, and possibly better than the standard treatment. Clinical trials may test such approaches as a new drug, a new combination of standard treatments, or new doses of current therapies. Your doctor can help you review all treatment options. For more information, see the Clinical Trials and Latest Research sections.

Treatment overview

In cancer care, different types of doctors often work together to create a patient’s overall treatment plan that combines different types of treatments. This is called a multidisciplinary team.

The goal of treatment for HCL and PLL is remission. Remission is the absence of leukemia symptoms and is also called “no evidence of disease” or NED. Descriptions of the most common treatment options for HCL and PLL are listed below. Treatment options and recommendations depend on several factors, including whether you have HCL or PLL, possible side effects, and your preferences and overall health. Your care plan may also include treatment for symptoms and side effects, an important part of cancer care. Take time to learn about all of your treatment options and be sure to ask questions about things that are unclear. Also, talk about the goals of each treatment with your doctor and what you can expect while receiving the treatment. Learn more about making treatment decisions.

Chemotherapy

Chemotherapy is the use of drugs to destroy cancer cells, usually by stopping the leukemia cells’ ability to grow and divide. Chemotherapy is given by a medical oncologist, a doctor who specializes in treating cancer with medication, or a hematologist, a doctor who specializes in treating blood disorders.

Systemic chemotherapy is delivered through the bloodstream to reach leukemia cells throughout the body. Common ways to give chemotherapy include an intravenous (IV) tube placed into a vein using a needle or in a pill or capsule that is swallowed (orally). A chemotherapy regimen (schedule) usually consists of a specific number of cycles given over a set period of time. A patient may receive one drug at a time or combinations of different drugs at the same time.

Drugs that are used to treat HCL include cladribine (Leustatin) and pentostatin (Nipent). For most people with HCL, both cladribine and pentostatin can bring a remission that lasts for many years and are the standard initial treatment for the disease.

PLL is treated with a combination of drugs, and several different regimens can be used. The specific regimen recommended for each patient is based on the type of chemotherapy the patient may have received previously and the possible side effects.

The side effects of chemotherapy depend on the individual and the dose used, but they can include fatigue, risk of infection, nausea and vomiting, hair loss, loss of appetite, and diarrhea. These side effects usually go away once treatment is finished.

Learn more about chemotherapy and preparing for treatment.  The medications used to treat cancer are continually being evaluated. Talking with your doctor is often the best way to learn about the medications prescribed for you, their purpose, and their potential side effects or interactions with other medications. Learn more about your prescriptions by using searchable drug databases.

Immunotherapy

Immunotherapy, also called biologic therapy, is designed to boost the body's natural defenses to fight the cancer. It uses materials made either by the body or in a laboratory to improve, target, or restore immune system function. Immunotherapy for HCL includes recombinant interferon alpha (Alferon, Intron A, Roferon-A). Learn more about immunotherapy.

Targeted therapy

Targeted therapy is a treatment that targets the leukemia’s specific genes, proteins, or the tissue environment that contributes to growth and survival. This type of treatment blocks the growth and spread of leukemia cells while limiting damage to healthy cells.

Recent studies show that not all cancers have the same targets. To find the most effective treatment, your doctor may run tests to identify the genes, proteins, and other factors involved in your leukemia. As a result, doctors can better match each patient with the most effective treatment whenever possible. In addition, many research studies are taking place now to find out more about specific molecular targets and new treatments directed at them. Learn more about targeted treatments.

A monoclonal antibody is a type of targeted therapy. It is directed against a specific protein in the leukemia cells, and it does not affect cells that don’t have that protein. Rituximab (Rituxan) is an antibody directed against the surface protein CD20. BL22 immunotoxin is an antibody that is designed to attach to the surface protein CD22 and deliver a toxin to the leukemia cell. Both rituximab and BL22 have been used to treat HCL that did not go into remission after the initial treatment. However, BL22 is not approved by the U.S. Food and Drug Administration (FDA) for the treatment of PLL and is only available in clinical trials. Alemtuzumab (Campath) is an antibody that targets the surface protein CD52 and has been used to treat PLL. Talk with your doctor about possible side effects for a specific medication and how they can be managed.

Surgery

Surgery to remove the spleen, which also makes white blood cells, is called a splenectomy and may be done for some patients. A surgical oncologist is a doctor who specializes in treating cancer using surgery. Learn more about surgery.

Stem cell transplantation/bone marrow transplantation

A stem cell transplant is a medical procedure in which bone marrow that contains leukemia is replaced by highly specialized cells, called hematopoietic stem cells, that develop into healthy bone marrow. Hematopoietic stem cells are blood-forming cells found both in the bloodstream and in the bone marrow. Today, this procedure is more commonly called a stem cell transplant, rather than bone marrow transplant, because it is the stem cells in the blood that are typically being transplanted, not the actual bone marrow tissue.

Before recommending transplantation, doctors will talk with the patient about the risks of this treatment and consider several other factors, such as the type of leukemia, results of any previous treatment, and patient’s age and general health. Transplantation is a higher-risk procedure. It is not used often for people with HCL and PLL because it is not always an effective therapy for these diseases and because many patients with HCL or PLL are older and the risks of the procedure are higher.

There are two types of stem cell transplantation depending on the source of the replacement blood stem cells: allogeneic (ALLO) and autologous (AUTO). ALLO uses donated stem cells, while AUTO uses the patient’s own stem cells. ALLO transplantation is sometimes considered for younger patients with PLL when chemotherapy was not effective. However, AUTO transplantation is rarely considered for patients with PLL or HCL.

In both types, the goal is to destroy all of the leukemia cells in the marrow, blood, and other parts of the body using high doses of chemotherapy and/or radiation therapy and then allow replacement blood stem cells to create healthy bone marrow. Learn more about stem cell and bone marrow transplantation.

Getting care for symptoms and side effects

HCL and PLL, as well as the treatments for these types of leukemia, often cause side effects. In addition to treatment to slow, stop, or eliminate the disease, an important part of care is relieving a person’s symptoms and side effects. This approach is called palliative or supportive care, and it includes supporting the patient with his or her physical, emotional, and social needs.

Palliative care can help a person at any stage of illness. People often receive treatment for the leukemia and treatment to ease side effects at the same time. In fact, patients who receive both often have less severe symptoms, better quality of life, and report they are more satisfied with treatment.

Palliative treatments vary widely and often include medication, nutritional changes, relaxation techniques, and other therapies. You may also receive palliative treatments similar to those meant to eliminate the leukemia, such as chemotherapy, surgery, and radiation therapy. Talk with your doctor about the goals of each treatment in your treatment plan.

Before treatment begins, talk with your health care team about the possible side effects of your specific treatment plan and supportive care options. And during and after treatment, be sure to tell your doctor or another health care team member if you are experiencing a problem so it is addressed as quickly as possible. Learn more about palliative care.

Refractory HCL and PLL

If HCL or PLL continue to worsen despite treatment, it is called refractory or resistant. Patients with this diagnosis are encouraged to talk with doctors who are experienced in treating refractory HCL or PLL, because there can be different opinions about the best treatment plan. Learn more about seeking a second opinion before starting treatment, so you are comfortable with the treatment plan chosen. This discussion may include clinical trials studying new treatments.

For HCL, your health care team may recommend a treatment plan that includes rituximab and/or BL22 immunotoxin. Supportive care will also be important to help relieve symptoms and side effects. In addition, it has recently been shown that almost all patients with HCL have a mutation in their leukemia cells in a gene called BRAF. A drug that stops a mutated BRAF gene from helping the leukemia grow and spread called vemurafenib (Zelboraf) has been successful for treating melanoma and a few patients with refractory HCL have received this drug. Talk with your doctor about your treatment options.

For most patients, a diagnosis of refractory HCL or PLL is very stressful and, at times, difficult to bear. Patients and their families are encouraged to talk about the way they are feeling with doctors, nurses, social workers, or other members of the health care team. It may also be helpful to talk with other patients, including through a support group.

Recurrence and the chance of remission

A remission is when HCL or PLL cannot be detected in the body and there are no symptoms. A remission can be temporary or permanent. This uncertainty leads to many survivors feeling worried or anxious that the disease will come back. While many remissions are permanent, it’s important to talk with your doctor about the possibility of the leukemia returning. Understanding the risk of recurrence and the treatment options may help you feel more prepared if the disease does return. Learn more about coping with the fear of recurrence

If HCL or PLL does return after the original treatment, it is called recurrent HCL or PLL. When this occurs, a cycle of testing will begin again to learn as much as possible about the recurrence. After testing is done, you and your doctor will talk about your treatment options. Often the treatment plan will include the therapies described above such as chemotherapy, immunotherapy, targeted therapy, and stem cell transplantation, but they may be used in a different combination or given at a different pace. For instance, cladribine and pentostatin can work again to treat HCL if it recurs after a long period of remission. Your doctor may also suggest clinical trials that are studying new ways to treat recurrent HCL or PLL.

People with recurrent HCL or PLL often experience emotions such as disbelief or fear. Patients are encouraged to talk with their health care team about these feelings and ask about support services to help them cope. Learn more about dealing with a recurrence.

If treatment fails

Recovery from HCL and PLL is not always possible. If treatment is not successful, the disease may be called advanced or terminal HCL or PLL.

This diagnosis is stressful, and this is difficult to discuss for many people. However, it is important to have open and honest conversations with your doctor and health care team to express your feelings, preferences, and concerns. The health care team is there to help, and many team members have special skills, experience, and knowledge to support patients and their families. Making sure a person is physically comfortable and free from pain is extremely important.

Patients who have advanced HCL or PLL and who are expected to live less than six months may want to consider a type of palliative care called hospice care. Hospice care is designed to provide the best possible quality of life for people who are near the end of life. You and your family are encouraged to think about where you would be most comfortable: at home, in the hospital, or in a hospice environment. Nursing care and special equipment can make staying at home a workable alternative for many families. Learn more about advanced cancer care planning.

After the death of a loved one, many people need support to help them cope with the loss. Learn more about grief and loss.

The next section helps explain clinical trials, which are research studies. Use the menu on the side of your screen to select About Clinical Trials, or you can select another section, to continue reading this guide.

Leukemia - B-cell Prolymphocytic Leukemia and Hairy Cell Leukemia - About Clinical Trials

This section has been reviewed and approved by the Cancer.Net Editorial Board, 06/2014

ON THIS PAGE: You will learn more about clinical trials, which are the main way that new medical approaches are tested to see how well they work. To see other pages, use the menu on the side of your screen.

Doctors and scientists are always looking for better ways to treat patients with B-cell leukemia. To make scientific advances, doctors create research studies involving volunteers, called clinical trials.

Many clinical trials are focused on new treatments, evaluating whether a new treatment is safe, effective, and possibly better than the current (standard) treatment. These types of studies evaluate new drugs, different combinations of existing treatments, new approaches to radiation therapy or surgery, and new methods of treatment. Patients who participate in clinical trials are often among the first to receive new treatments before they are widely available. However, there is no guarantee that the new treatment will be safe, effective, or better than a standard treatment.

There are also clinical trials that study new ways to ease symptoms and side effects during treatment and manage the late effects that may occur after treatment. Talk with your doctor about clinical trials regarding side effects. In addition, there are ongoing studies about ways to prevent the disease.

Patients decide to participate in clinical trials for many reasons. For some patients, a clinical trial is the best treatment option available. Because standard treatments are not perfect, patients are often willing to face the added uncertainty of a clinical trial in the hope of a better result. Other patients volunteer for clinical trials because they know that these studies are the only way to make progress in treating HCL and PLL. Even if they do not benefit directly from the clinical trial, their participation may benefit future patients with HCL and PLL.

Sometimes people have concerns that, by participating in a clinical trial, they may receive no treatment by being given a placebo or a “sugar pill.” The use of placebos in cancer clinical trials is rare. When a placebo is used in a study, it is done with the full knowledge of the participants. Find out more about placebos in cancer clinical trials.

To join a clinical trial, patients must participate in a process known as informed consent. During informed consent, the doctor should list all of the patient’s options so that the person understands how the new treatment differs from the standard treatment. The doctor must also list all of the risks of the new treatment, which may or may not be different from the risks of standard treatment. Finally, the doctor must explain what will be required of each patient in order to participate in the clinical trial, including the number of doctor visits, tests, and the schedule of treatment.

For specific topics being studied for B-cell leukemia, learn more in the Latest Research section.

Patients who participate in a clinical trial may stop participating at any time for any personal or medical reason. This may include that the new treatment is not working or there are serious side effects. Clinical trials are also closely monitored by experts who watch for any problems with each study. It is important that patients participating in a clinical trial talk with their doctor and researchers about who will be providing their treatment and care during the clinical trial, after the clinical trial ends, and/or if the patient chooses to leave the clinical trials before it ends.

Cancer.Net offers a lot of information about clinical trials in other areas of the website, including a complete section on clinical trials and places to search for clinical trials for a specific type of leukemia.

The next section helps explain the areas of research going on today about these types of leukemia. Use the menu on the side of your screen to select Latest Research, or you can select another section, to continue reading this guide.

Leukemia - B-cell Prolymphocytic Leukemia and Hairy Cell Leukemia - Latest Research

This section has been reviewed and approved by the Cancer.Net Editorial Board, 06/2014

ON THIS PAGE: You will read about the scientific research being done now to learn more about HCL and PLL and how to treat these types of leukemia. To see other pages, use the menu on the side of your screen.

Doctors are working to learn more about HCL and PLL, ways to prevent these types of leukemia, how to best treat each disease, and how to provide the best care to people diagnosed with HCL or PLL. The following areas of research may include new options for patients through clinical trials. Always talk with your doctor about the diagnostic and treatment options best for you.

Targeted therapy. New treatments are being tested in clinical trials, including those that use angiogenesis inhibitors and monoclonal antibodies. Angiogenesis inhibitors are focused on stopping angiogenesis, which is the process of making new blood vessels. As discussed in the Treatment Options section, BL22 and LMB-2 are monoclonal antibodies linked to toxins that are designed to attach to the surface proteins of leukemia cells. Doctors are using these and other monoclonal antibodies in clinical trials for people with HCL when other treatments no longer work. In addition, drugs that target the BRAF gene are being studied for refractory HCL. In the future, finding out whether this gene is mutated also may help diagnose HCL.

In addition, ibrutinib (Imbruvica) is a new drug targeting an enzyme called Bruton’s tyrosine kinase, which helps B-cell leukemias and lymphomas grow. It is being studied for several B-cell disorders and clinical trials in PLL and HCL will be done as well.

Supportive care. Clinical trials are underway to find better ways of reducing symptoms and side effects of current treatments in order to improve patients’ comfort and quality of life.

Looking for More About the Latest Research?

If you would like additional information about the latest areas of research regarding leukemia, explore these related items that take you outside of this guide:

  • To find clinical trials specific to your diagnosis, talk with your doctor or search online clinical trial databases now.
  • Review research on CLL announced at the 2014 and 2013 ASCO Annual Meetings.
  • Visit ASCO’s CancerProgress.Net website to learn more about the historical pace of research for leukemia. Please note this link takes you to a separate ASCO website.

The next section addresses how to cope with the symptoms of the disease or the side effects of its treatment. Use the menu on the side of your screen to select Coping with Side Effects, or you can select another section, to continue reading this guide.

Leukemia - B-cell Prolymphocytic Leukemia and Hairy Cell Leukemia - Coping with Side Effects

This section has been reviewed and approved by the Cancer.Net Editorial Board, 06/2014

ON THIS PAGE: You will find out more about steps to take to help cope with physical, social, and emotional side effects. This page includes several links outside of this guide to other sections of this website. To see other pages, use the menu on the side of your screen.

Fear of treatment side effects is common after a diagnosis of HCL or PLL, but it may help to know that preventing and controlling side effects is a major focus of your health care team. This is called palliative or supportive care, and it is an important part of the overall treatment plan, regardless of the stage of disease.

Common side effects from each treatment option for HCL and PLL are described in detail within the Treatment Options section. Learn more about the most common side effects of leukemia and different treatments, along with ways to prevent or control them. Side effects depend on a variety of factors, including the length and dosage of treatment(s), and your overall health.

Before treatment begins, talk with your doctor about possible side effects of each type of treatment you will be receiving. Ask which side effects are most likely to happen, when they are likely to occur, and what can be done to prevent or relieve them. And, ask about the level of caregiving you may need during treatment and recovery, as family members and friends often play an important role in the care of a person with HCL or PLL. Learn more about caregiving.

In addition to physical side effects, there may be emotional and social effects as well. Patients and their families are encouraged to share their feelings with a member of their health care team who can help with coping strategies, including concerns about managing the cost of your cancer care

During and after treatment, be sure to tell the health care team about the side effects you experience, even if you feel they are not serious. Sometimes, side effects can last beyond the treatment period, called a long-term side effect. A side effect that occurs months or years after treatment is called a late effect. Treatment of both types of effects is an important part of survivorship care. Learn more by reading the After Treatment section or talking with your doctor. 

The next section helps explain medical tests and check-ups needed after finishing treatment for leukemia. Use the menu on the side of your screen to select After Treatment, or you can select another section, to continue reading this guide.

Leukemia - B-cell Prolymphocytic Leukemia and Hairy Cell Leukemia - After Treatment

This section has been reviewed and approved by the Cancer.Net Editorial Board, 06/2014

ON THIS PAGE: You will read about your medical care after treatment is finished and why this follow-up care is important. To see other pages, use the menu on the side of your screen.

After treatment for HCL or PLL ends, talk with your doctor about developing a follow-up care plan. This plan may include regular physical examinations, blood tests, bone marrow biopsies, and possibly scans or other imaging tests to monitor your recovery for the coming months and years.

In addition to watching for a recurrence, doctors will also monitor you for possible side effects during follow-up care. Talk with your doctor about what you can expect based on your specific treatment plan. Several long-term side effects from treatments for HCL and PLL may occur:

  • Lung damage from certain drugs or radiation therapy to the lungs.
  • A weakened heart muscle from higher doses of doxorubicin (Adriamycin) or radiation therapy to the chest.
  • Infertility (inability to have a child) or premature menopause from high-dose cyclophosphamide (Neosar) or other chemotherapy.
  • A secondary leukemia or other type of cancer are those that develop because of the treatment for the first type of cancer and are more common after treatment with chemotherapy. Specifically, people treated for CLL are at a higher risk for developing skin cancer and should protect their skin from the sun. They also have a higher risk of lung cancer, and smoking is strongly discouraged.

ASCO offers cancer treatment summary forms to help keep track of the treatment you received and develop a survivorship care plan once treatment is completed.

People recovering from HCL and PLL are encouraged to follow established guidelines for good health, such as maintaining a healthy weight, not smoking, eating a balanced diet, and having recommended cancer screening tests. People experiencing a long-term remission are encouraged to follow cancer screening recommendations for the general population to watch for other types of cancer. Talk with your doctor to develop a plan that is best for your needs. Moderate physical activity can help rebuild your strength and energy level. Your doctor can help you create an appropriate exercise plan based upon your needs, physical abilities, and fitness level. Learn more about the next steps to take in survivorship, including making positive lifestyle changes.

The next section offers a list of questions you may want to ask. Use the menu on the side of your screen to select Questions to Ask the Doctor, or you can select another section, to continue reading this guide.

Leukemia - B-cell Prolymphocytic Leukemia and Hairy Cell Leukemia - Questions to Ask the Doctor

This section has been reviewed and approved by the Cancer.Net Editorial Board, 06/2014

ON THIS PAGE: You will find some questions to ask your doctor or other members of your health care team, to help you better understand your diagnosis, treatment plan, and overall care. To see other pages, use the menu on the side of your screen.

Talking often with the doctor is important to make informed decisions about your health care. These suggested questions are a starting point to help you learn more about your care and treatment. You are also encouraged to ask additional questions that are important to you. You may want to print this list and bring it to your next appointment, or download Cancer.Net’s free mobile app for an e-list and other interactive tools to manage your care.

  • What is the exact type of leukemia that I have?
  • Can you explain my pathology report (laboratory test results) to me?
  • What is the progression or development of this disease? Is it possible to stop or slow the growth of the cancer? Is it curable?
  • How can my symptoms be controlled? For how long?
  • What are my treatment options?
  • What clinical trials are open to me? Where are they located, and how do I find out more about them?
  • What treatment plan do you recommend? Why?
  • What is the goal of each treatment? Is it to eliminate the leukemia, help relieve my symptoms, or both?
  • Who will be part of my health care team, and what does each member do?
  • Who will be coordinating my overall treatment and follow-up care?
  • What are the possible side effects of this treatment, both in the short term and the long term?
  • How will this treatment affect my daily life? Will I be able to work, exercise, and perform my usual activities?
  • Could this treatment affect my sex life? If so, how and for how long?
  • Could this treatment affect my ability to become pregnant or have children? If so, should I talk with a fertility specialist before treatment begins?
  • If I’m worried about managing the costs related to my cancer care, who can help me with these concerns?
  • How can I keep myself as healthy as possible during and after treatment?
  • What follow-up tests will I need, and how often will I need them?
  • What support services are available to me? To my family?
  • Is there concern that other members of my family could get this disease? Is genetic testing available?
  • Whom should I call for questions and problems?

The next section offers some more resources that may be helpful to you. Use the menu on the side of your screen to select Additional Resources, or you can select another section, to continue reading this guide.

Leukemia - B-cell Prolymphocytic Leukemia and Hairy Cell Leukemia - Additional Resources

This section has been reviewed and approved by the Cancer.Net Editorial Board, 06/2014

ON THIS PAGE: You will find some helpful links to other areas of Cancer.Net that provide information about cancer care and treatment. This is the final page of Cancer.Net’s Guide to B-Cell Leukemia. To go back and review other pages, use the menu on the side of your screen.

Cancer.Net includes many other sections about the medical and emotional aspects of leukemia, both for the person diagnosed and their family members and friends. This website is meant to be a resource for you and your loved ones from the time of diagnosis, through treatment, and beyond. Here are a few sections that may get you started in exploring the rest of Cancer.Net:

Search for a specialist in your local area using this free database of doctors from the American Society of Clinical Oncology.

Review dictionary articles to help understand medical phrases and terms used in medical care and treatment.

Read more about the first steps to take when newly diagnosed with leukemia.

Find out more about clinical trials as a treatment option.

Learn more about coping with the emotions that leukemia can bring, including those within a family or a relationship.

Find a national, not-for-profit advocacy organization that may offer additional information, services, and support for people with leukemia.

Explore next steps a person can take after active treatment is complete.

This is the end of Cancer.Net’s Guide to B-Cell Leukemia. Use the menu on the side of your screen to select another section to continue reading this guide.